At a glance
- Originator Sanofi-Synthelabo
- Class Antiarrhythmics; Antihypertensives; Benzopyrans
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Hypertension; Myocardial ischaemia
Most Recent Events
- 02 Jun 1995 Discontinued-I for Asthma in France (Unknown route)
- 02 Jun 1995 Discontinued-I for Hypertension in France (Unknown route)
- 02 Jun 1995 Discontinued-I for Myocardial ischaemia in France (Unknown route)